2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1759

Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis
Abstract Number: 1517

Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
Abstract Number: 460

Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Abstract Number: 1485

Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
Abstract Number: 464

Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
Abstract Number: 1320

Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus
Abstract Number: 513

Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics
Abstract Number: 2478

Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies
Abstract Number: 2063

Analysis of the Fibromyalgia Rapid Screening Tool Spanish Version to Detect Fibromyalgia in Primary Health Care Centers
Abstract Number: 615

Analysis of the Gut Transcriptome in HLA-B27 Transgenic Rats By RNA-Seq Reveals Prominent Interferon and IL-23/IL-17 Axis Signatures
Abstract Number: 237

Analysis of Vitamin D Receptor Gene Polymorphisms and Bone Mineral Density in a Population of Women with Rheumatoid Arthritis in Use of Steroid
Abstract Number: 2521

Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Abstract Number: 2436

Analytical and Clinical Evaluation of an Immunoassay for Estimating Immunogenicity of Infliximab and Etanercept in Indian Population
Abstract Number: 180

Analytical Comparison Between Point of Care Uric Acid Testing Meters
Abstract Number: 1029

Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].